A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

NCT ID: NCT04696432

Last Updated: 2025-05-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-27
• Study Completion Date: 2023-12-30

Brief Summary

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.

Detailed Description

This is a single-arm, open label, phase I study to evaluate the safety and preliminary efficacy of C-CAR039 in adults with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. 10 patients are planned to be enrolled. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of C-CAR039. Following manufacture of the drug product, subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide prior to C-CAR039 infusion. All subjects who have received C-CAR039 infusion will be followed for up to 24 months

Conditions

Non-Hodgkin's B-cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Prizloncabtagene autoleucel

Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.

Group Type: EXPERIMENTAL

Prizloncabtagene autoleucel

Intervention Type: BIOLOGICAL

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Interventions

Prizloncabtagene autoleucel

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Intervention Type: BIOLOGICAL

Other Intervention Names

C-CAR039

Eligibility Criteria

Inclusion Criteria

1. Age 18-70 years (include 18 and 70), male or female;

2. Expected survival ≥ 12 weeks

3. ECOG score 0-2

4. CD19 or CD20 positive B-NHL confirmed by cytology or histology according to WHO2016 criteria, including DLBCL, PMBCL, tFL, FL and MCL;

5. Relapsed or refractory disease after ≥ 2 lines (for FL, at least 3 lines) of standard therapy or relapsed after autologous stem cell transplantation (ASCT)

6. For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause of intolerance should be recorded;

7. No contraindications of apheresis.

8. At least one measurable lesion according to Lugano 2014 criteria;

9. Adequate organ and bone marrow function.

10. The patient volunteered to participate in the study and signed the Informed Consent;

Exclusion Criteria

1. Malignant tumors other than B-NHL within 5 years prior to screening, except cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery;

2. Active HIV, HBV, HCV or treponema pallidum infection ;

3. Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy;

4. Any uncontrolled active disease that prevents participation in the trial

5. Any situation that the investigator believes will harm the safety of the subjects or interfere with the purpose of the study

6. Female subjects who have been pregnant or breastfeeding, or who plan to conceive during or within 1 year after treatment, or male subjects' partner plans to conceive within 1 year after C-CAR039 infusion;

7. Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;

8. Patients who have been previously infected with tuberculosis;

9. Administered Corticosteroids and/or other immunosuppressants within 7 days before apheresis. and 5 days before the infusion of C-CAR039;

10. Patients with central nervous system involvement;

11. Any systemic antitumor therapy performed within 2 weeks before enrollment;

12. Those with medical conditions that prevent them from signing the written informed consent or from complying with the study procedures; or those who are unwilling or unable to comply with the study requirements;

13. Other conditions was considered unsuitable for enrollment by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai AbelZeta Ltd.

INDUSTRY

Sponsor Role: collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lanfang Li, PhD&MD

Role: PRINCIPAL_INVESTIGATOR

Tianjin Medical University Cancer Institute & Hosipital

Locations

Tianjin Medical University Cancer Institute & Hosipital

Tianjin, Tianjin Municipality, China

Countries

China

References

Yu W, Li P, Zhou L, Yang M, Ye S, Zhu D, Huang J, Yao X, Zhang Y, Li L, Zhao J, Zhu K, Li J, Zheng C, Lan L, Wan H, Yao Y, Zhang H, Zhou D, Jin J, Liang A. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2025 Apr 3;145(14):1526-1535. doi: 10.1182/blood.2024026401.

Reference Type: DERIVED

PMID: 39813680 (View on PubMed)

Other Identifiers

0702-021

Identifier Type: -

Identifier Source: org_study_id